Your shopping cart is currently empty

Z944 is a T-type calcium channel antagonist with potential applications in pain management. In both epileptic and non-epileptic rats, Z944 disrupts prepulse inhibition. Additionally, it corrects cross-modal sensory and visual recognition memory deficits in Strasbourg genetic absence epilepsy rats. In a neuropathic pain rat model, Z944 restores cortical synchrony and thalamocortical connectivity. In the amygdala kindling model, it delays seizure progression.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Z944 is a T-type calcium channel antagonist with potential applications in pain management. In both epileptic and non-epileptic rats, Z944 disrupts prepulse inhibition. Additionally, it corrects cross-modal sensory and visual recognition memory deficits in Strasbourg genetic absence epilepsy rats. In a neuropathic pain rat model, Z944 restores cortical synchrony and thalamocortical connectivity. In the amygdala kindling model, it delays seizure progression. |
| Synonyms | Ulixacaltamide hydrochloride, NKU8XML45M |
| Molecular Weight | 420.35 |
| Formula | C19H28Cl2FN3O2 |
| Cas No. | 1797986-84-5 |
| Smiles | Cl.O=C(NCC1CCN(CC(=O)NC(C)(C)C)CC1)C=2C=C(F)C=C(Cl)C2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.